Gilead Sciences in the news
Developing innovative healthcare solutions
Tamtam found 20 recent articles about Gilead Sciences.
- Gilead Sciences, Inc. $GILD Stock Holdings Lifted by Ieq Capital LLC
Gilead Sciences saw increased institutional investment, reported strong Q3 earnings beating analyst estimates, and announced a quarterly dividend, while some executives sold shares.
- Advisors Asset Management Inc. Makes New Investment in Gilead Sciences, Inc. $GILD
Advisors Asset Management Inc. made a new $35.45 million investment in Gilead Sciences, Inc. during the third quarter.
- 203,673 Gilead Sciences, Inc. $GILD Shares Sold by Public Sector Pension Investment Board
Gilead Sciences experienced institutional investor activity, strong Q3 earnings, insider stock sales, new analyst price targets, and declared a quarterly dividend.
- Gilead Opens Foster City Research Center for Cancer Study
Gilead Sciences opened a new 182,000-square-foot research center in Foster City to accelerate drug discovery in oncology and inflammation, featuring flexible labs and advanced technology.
- Gilead Sciences (GILD) Stock: $168.98, Down 0.75% Nov 18
Gilead Sciences stock experienced a modest 0.75% decline on light volume, consolidating near the top of its recent recovery.
- Is the Long-Acting HIV Launch Gaining Pace at Gilead (NASDAQ:GILD)?
Gilead's new long-acting HIV prevention therapy is experiencing rapid commercial uptake, contributing to strong financial results and a strategic shift in HIV care.
- Gilead Partnership Helps Provide Support for PBC Caregivers
Gilead Sciences partnered with Calm to provide free mental wellbeing resources for PBC patients and their caregivers, highlighting the challenges through a caregiver's personal story.
- Where Could Gilead’s Next Growth Come From?
Gilead Sciences is relying on its rapidly growing HIV prevention drugs to offset a significant revenue hit from its top-selling drug, Biktarvy, due to Medicare price reductions in 2028.
- How Investors Are Reacting To Gilead Sciences (GILD) HIV Prevention Expansion
Gilead Sciences expands its HIV prevention portfolio with new drugs to mitigate Biktarvy pricing pressure and aims for earnings recovery through its HIV and oncology platforms.
- 1,321,457 Gilead Sciences, Inc. $GILD Shares Sold by Voya Investment Management LLC
Gilead Sciences saw a major institutional investor reduce its holdings, reported strong Q3 earnings, declared a dividend, and experienced insider stock sales, while analysts maintain a positive outlook.
- Gilead Sciences, Inc. $GILD Shares Purchased by Boston Partners
Boston Partners grew its stake in Gilead Sciences by 8.4% in the third quarter, holding 6.5 million shares.
- TD Cowen Reiterates Buy Rating on Gilead Sciences (GILD)
TD Cowen reaffirmed its Buy rating and $175.00 price target for Gilead Sciences (GILD).
- How Investors Are Reacting To Gilead Sciences (GILD) Strong HIV Trial Data
Gilead Sciences released strong HIV trial data for lenacapavir, indicating a shift towards new HIV and oncology products for growth, with analysts forecasting significant revenue and earnings increases by 2029.
- Insider Selling: Gilead Sciences (NASDAQ:GILD) CFO Sells $514,410.00 in Stock
Gilead Sciences' CFO sold over $500,000 in stock, while the company reported strong Q3 earnings, announced a dividend, and received a 'Moderate Buy' analyst rating.
- Gilead Sciences (GILD) officer exercises 25,000 options and sells 28,000 shares.
A Gilead Sciences officer exercised stock options and sold shares.
- Gilead Sciences chief comm & corp aff officer Mercier sells $4.7M shares
Gilead Sciences' Chief Communications & Corporate Affairs Officer sold over $4.7 million in shares while also acquiring shares through options, as the company reported strong financial results and received positive analyst revisions.
- Gilead: Growth Supports A Hold Despite A Valuation Premium
Gilead Sciences faces a potential downside despite growth in its antiviral franchise, as oncology and GI segments decline, and its pipeline is crucial for future value, while the company trades at a valuation premium.
- What Gilead Sciences Doubters Missed
Gilead Sciences' stock is up 40.3% this year due to strong HIV and oncology demand, despite investor debates over future growth and pricing pressures.
- Gilead Sciences (GILD) Grants Royalty Free Ebola Drug Licenses For Lower Income Countries
Gilead Sciences granted royalty-free licenses for its investigational Ebola drug obeldesivir in low-income countries and updated remdesivir licenses to improve global access.
- Gilead Sciences stock: company signs Ebola drug licenses
Gilead Sciences signed royalty-free voluntary licensing agreements with three generic manufacturers for its investigational antiviral obeldesivir for Ebola Bundibugyo virus disease.
Articles collected by Tamtam and kept when they are about the company, newest first. Each links to its source.
Selling to companies like Gilead Sciences?
Tamtam finds the companies that match your ideal customer, researches each account and tells you who to contact and when.
Find similar companies